Immune cell therapy for children with certain solid tumors
Part of Cancer, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 1 to under 24 years and weigh at least 10 kg
- Diagnosis of rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor that has returned or not responded to standard treatment
- Cancer is measurable or detectable on imaging
- Cancer has not spread to the brain or spinal cord
- Reasonably good physical function and organ health (heart, lungs, liver, kidneys, blood counts)
- No active infections or HIV
- No prior stem cell transplant from a donor
- Must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
This trial tests a new type of immune therapy (CAR T-cells) that is engineered to find and attack neuroblastoma cells by targeting specific markers (GD2, PSMA, and CD276) on the cancer cells. It is for patients whose cancer has not responded to standard treatments and who are healthy enough to receive this experimental cell therapy.
This trial tests a new immune therapy using your own cells (called B7-H3 CAR T cells) to treat solid tumors that haven't responded to other treatments. It may help children and young adults with certain cancers that are hard to cure.
This trial tests a type of immunotherapy using special white blood cells (T-cells) that are trained to find and attack cancer cells. It is for children and young adults with high-risk solid tumors that have not gone away or have come back after standard treatment.
Hear when a new Rhabdomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.